Ultan Mcdermott BSc, MBBS, MD, PhD

Ultan McDermott became Chief Scientist at AstraZeneca in 2017 with a focus on drug resistance in cancer, after eight years at the Wellcome Sanger Institute (seven of those as group leader). Ultan continues to maintain strong working relationships with colleagues in the Cancer, Ageing and Somatic Mutation programme at the Sanger as a member of Honorary Faculty. He also holds an Honorary Consultant post in the Oncology department at Addenbrooke’s Hospital in Cambridge, where he treats colorectal cancer patients. Ultan joined the Sanger Institute in 2009 as a clinical research fellow and was appointed to the faculty as a Group Leader in 2010 with the award of a Cancer Research UK Clinician Scientist Fellowship. Previously he worked as a postdoctoral fellow with Jeff Settleman at Massachusetts General Hospital Cancer Center, Boston on high-throughput cancer cell line drug screens and resistance mechanisms. He is a Fellow of the Royal College of Physicians.